Literature DB >> 28574879

Possible Treatment Approach to an Extravasation of 177Lu-PSMA-617.

Carl Diedrich Schlenkhoff1, Markus Essler, Hojjat Ahmadzadehfar.   

Abstract

A rare accident of a subcutaneous extravasation in the elbow with 4280 MBq Lu-PSMA-617 occurred in our clinic. We tried to reduce the damage by warming the elbow for 12 hours, then cooling it, and recommended the patient avoid exercises with the elbow for the next 3 days. We recognized a good resorption of the radionuclide in the scintigraphic imaging in the first 2 days. No pain, burning, or necrosis occurred. The administered therapy afterward showed an adequate decrease in the tumor marker level.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28574879     DOI: 10.1097/RLU.0000000000001715

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

1.  177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT.

Authors:  Christophe Mazzara; Julien Salvadori; Florian Ritzenthaler; Simon Martin; Clémence Porot; Alessio Imperiale
Journal:  EJNMMI Phys       Date:  2022-05-03

2.  Extravasation of [177Lu]Lu-DOTATOC: case report and discussion.

Authors:  Anne Kirstine Arveschoug; Anne Charlotte Bekker; Peter Iversen; Henrik Bluhme; Gerda Elisabeth Villadsen; Peter Frøhlich Staanum
Journal:  EJNMMI Res       Date:  2020-06-23       Impact factor: 3.138

3.  Tissue dose estimation after extravasation of 177Lu-DOTATATE.

Authors:  Perrine Tylski; Géraldine Pina-Jomir; Claire Bournaud-Salinas; Patrice Jalade
Journal:  EJNMMI Phys       Date:  2021-03-31

4.  EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.

Authors:  Katarina Sjögreen Gleisner; Nicolas Chouin; Pablo Minguez Gabina; Francesco Cicone; Silvano Gnesin; Caroline Stokke; Mark Konijnenberg; Marta Cremonesi; Frederik A Verburg; Peter Bernhardt; Uta Eberlein; Jonathan Gear
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-14       Impact factor: 10.057

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.